Consolidated Statements of Operations - USD ($) shares in Thousands, $ in Thousands	12 Months Ended
	Dec. 31, 2025	Dec. 31, 2024	Dec. 31, 2023
Operating expenses:
Research and development	$ 131,980	$ 215,673	$ 261,809
Research and development related success payments and contingent consideration	29,432	(8,881)	(48,981)
General and administrative	44,296	64,040	73,299
Impairment of long-lived assets	44,611	1,891	7,014
Total operating expenses	250,319	272,723	293,141
Loss from operations	(250,319)	(272,723)	(293,141)
Interest income, net	3,848	10,471	9,938
Other income (expense), net	2,305	(4,507)	(52)
Net loss	$ (244,166)	$ (266,759)	$ (283,255)
Net loss per common share - basic	$ (0.96)	$ (1.16)	$ (1.46)
Net loss per common share - diluted	$ (0.96)	$ (1.16)	$ (1.46)
Weighted-average number of common shares - basic	253,234	230,891	194,541
Weighted-average number of common shares - diluted	253,234	230,891	194,541